The Clinical Characteristics of New-Onset Epilepsy in the Elderly and Risk Factors for Treatment Outcomes of Antiseizure Medications
ObjectiveTo describe the clinical characteristics of elderly patients with new-onset epilepsy in a Class A tertiary comprehensive hospital in north China and evaluate the treatment outcomes of antiseizure medications (ASMs). This study focuses on investigating the factors affecting the treatment out...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.819889/full |
| _version_ | 1818324476838805504 |
|---|---|
| author | Jing Qi Xiao Liu Na Xu Qun Wang Qun Wang Qun Wang |
| author_facet | Jing Qi Xiao Liu Na Xu Qun Wang Qun Wang Qun Wang |
| author_sort | Jing Qi |
| collection | DOAJ |
| description | ObjectiveTo describe the clinical characteristics of elderly patients with new-onset epilepsy in a Class A tertiary comprehensive hospital in north China and evaluate the treatment outcomes of antiseizure medications (ASMs). This study focuses on investigating the factors affecting the treatment outcomes, guiding the drug treatment, and judging the prognosis of elderly epilepsy patients.MethodsWe included patients aged 60 years or older at the time of their first seizure between January 2014 and August 2020. Demographic characteristics, effects of ASM, and the proportion of 1-year and long-term seizure freedom were reported. The univariate analysis and binary logistic regression were used to identify factors potentially influencing treatment outcomes.ResultsA total of 326 patients (median age 65 years, 67.2% men) were included. Moreover, 185 (56.7%) patients who received the first ASM monotherapy achieved 1 year of seizure freedom in the early stage. Compared with structural etiology, unknown etiology was associated with a higher likelihood of early seizure freedom (odds ratio [OR] = 0.545; p < 0.05). Conversely, comorbid intracranial malignant tumors, taking carbamazepine (CBZ), and sodium valproate (VPA) were associated with a lower likelihood of seizure freedom (OR = 3.527 vs. 6.550 vs. 8.829; p < 0.05). At long-term follow-up, 263 (80.6%) patients achieved seizure freedom, with 79.8% on monotherapy.ConclusionsElderly patients with new-onset epilepsy responded well to the initial ASMs treatment. Patients with intracranial malignant tumors and prescribed VPA and CBZ were less likely to achieve early seizure freedom, while those with unknown etiology had higher probabilities of achieving early seizure freedom than those with structural etiology. |
| first_indexed | 2024-12-13T11:29:12Z |
| format | Article |
| id | doaj.art-72a2c0b0b1c544aba34674eba4a0ddce |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-13T11:29:12Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-72a2c0b0b1c544aba34674eba4a0ddce2022-12-21T23:48:03ZengFrontiers Media S.A.Frontiers in Neurology1664-22952022-02-011310.3389/fneur.2022.819889819889The Clinical Characteristics of New-Onset Epilepsy in the Elderly and Risk Factors for Treatment Outcomes of Antiseizure MedicationsJing Qi0Xiao Liu1Na Xu2Qun Wang3Qun Wang4Qun Wang5Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaNational Center for Clinical Medicine of Neurological Diseases, Beijing, ChinaCollaborative Innovation Center for Brain Disorders, Beijing Institute of Brain Disorders, Capital Medical University, Beijing, ChinaObjectiveTo describe the clinical characteristics of elderly patients with new-onset epilepsy in a Class A tertiary comprehensive hospital in north China and evaluate the treatment outcomes of antiseizure medications (ASMs). This study focuses on investigating the factors affecting the treatment outcomes, guiding the drug treatment, and judging the prognosis of elderly epilepsy patients.MethodsWe included patients aged 60 years or older at the time of their first seizure between January 2014 and August 2020. Demographic characteristics, effects of ASM, and the proportion of 1-year and long-term seizure freedom were reported. The univariate analysis and binary logistic regression were used to identify factors potentially influencing treatment outcomes.ResultsA total of 326 patients (median age 65 years, 67.2% men) were included. Moreover, 185 (56.7%) patients who received the first ASM monotherapy achieved 1 year of seizure freedom in the early stage. Compared with structural etiology, unknown etiology was associated with a higher likelihood of early seizure freedom (odds ratio [OR] = 0.545; p < 0.05). Conversely, comorbid intracranial malignant tumors, taking carbamazepine (CBZ), and sodium valproate (VPA) were associated with a lower likelihood of seizure freedom (OR = 3.527 vs. 6.550 vs. 8.829; p < 0.05). At long-term follow-up, 263 (80.6%) patients achieved seizure freedom, with 79.8% on monotherapy.ConclusionsElderly patients with new-onset epilepsy responded well to the initial ASMs treatment. Patients with intracranial malignant tumors and prescribed VPA and CBZ were less likely to achieve early seizure freedom, while those with unknown etiology had higher probabilities of achieving early seizure freedom than those with structural etiology.https://www.frontiersin.org/articles/10.3389/fneur.2022.819889/fullantiseizure medicationstreatment outcomeselderlynew-onset epilepsyrisk factor |
| spellingShingle | Jing Qi Xiao Liu Na Xu Qun Wang Qun Wang Qun Wang The Clinical Characteristics of New-Onset Epilepsy in the Elderly and Risk Factors for Treatment Outcomes of Antiseizure Medications Frontiers in Neurology antiseizure medications treatment outcomes elderly new-onset epilepsy risk factor |
| title | The Clinical Characteristics of New-Onset Epilepsy in the Elderly and Risk Factors for Treatment Outcomes of Antiseizure Medications |
| title_full | The Clinical Characteristics of New-Onset Epilepsy in the Elderly and Risk Factors for Treatment Outcomes of Antiseizure Medications |
| title_fullStr | The Clinical Characteristics of New-Onset Epilepsy in the Elderly and Risk Factors for Treatment Outcomes of Antiseizure Medications |
| title_full_unstemmed | The Clinical Characteristics of New-Onset Epilepsy in the Elderly and Risk Factors for Treatment Outcomes of Antiseizure Medications |
| title_short | The Clinical Characteristics of New-Onset Epilepsy in the Elderly and Risk Factors for Treatment Outcomes of Antiseizure Medications |
| title_sort | clinical characteristics of new onset epilepsy in the elderly and risk factors for treatment outcomes of antiseizure medications |
| topic | antiseizure medications treatment outcomes elderly new-onset epilepsy risk factor |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2022.819889/full |
| work_keys_str_mv | AT jingqi theclinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications AT xiaoliu theclinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications AT naxu theclinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications AT qunwang theclinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications AT qunwang theclinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications AT qunwang theclinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications AT jingqi clinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications AT xiaoliu clinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications AT naxu clinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications AT qunwang clinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications AT qunwang clinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications AT qunwang clinicalcharacteristicsofnewonsetepilepsyintheelderlyandriskfactorsfortreatmentoutcomesofantiseizuremedications |